Clopidogrel Response Analysis: Thromboelastography

How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 176 CE courses, most popular
$109Add to cart
Pick Your Courses
Up to 8 CE hours
$55Add to cart
Individual course$25Add to cart
Need multiple seats for your university or lab? Get a quote
The page below is a sample from the LabCE course Antiplatelet Medication Response Testing: Aspirin and Clopidogrel. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Antiplatelet Medication Response Testing: Aspirin and Clopidogrel (online CE course)
Clopidogrel Response Analysis: Thromboelastography

Thromboelastography (TEG) is an assay that measures the visco-elastic properties of whole blood clot formation under low shear stress. This testing is normally used for surgical purposes to assess the quality of clot formation. However, a modified TEG method can be used to assess an individual's response to antiplatelet therapy.
Agonists are added to a whole blood sample to begin the thrombotic process. The instrument has a pin attached to a tension wire which, when lowered into a rotating cup, causes thrombi formation. The thrombi create a tension on the wire, which is converted into electrical signals that create graphical and numerical outputs in a curve plot by the analyzer. When testing for clopidogrel response, the test is run with ADP-, fibrin-, and kaolin-coated cups.
Evaluations of patient results are compared to the manufacturer's reagents for each system. Typically, a lack of inhibition of thrombus formation would indicate resistance to clopidogrel. A cut-off value that determines non-responsiveness (resistance) to antiplatelet therapy must be established or verified by the testing laboratory.
Thromboelastography devices such as the TEG® and RoTem® provide point-of-care monitoring of patient coagulopathic status. When clopidogrel response is in question, TEG-platelet mapping (a modification of TEG) can also be used to quantify the effect of this antiplatelet drug in patients.